A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)

Exclusion Criteria

• •1. Alcohol consumption \> 14 units/week for females and 21 units/week for males
• •2. Hepatocellular carcinoma (HCC) or suspicion of HCC
• •3. Presence of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV)
• •4. Renal impairment (creatinine \> 1.5 x ULN) or hepatorenal syndrome
• •5. Chronic pancreatitis
• •6. Hospitalization for liver disease within 60 days of the baseline visit
• •7. Previously diagnosed diabetes / treatment with insulin sensitizing agents
• •8. Severe or morbid obesity (BMI\>40kg/m2)
• •9. ALT or AST \> 10 times ULN
• •10. Liver transplant recipients
• •11. Corticosteroids in the past 30 days
• •12. Any participant who has received any investigational drug or device within 30 days of dosing, or who is scheduled to receive another investigational drug or device during the course of this trial
• •13. A history of a malignancy other than treated basal cell or squamous cell carcinoma of the skin; those with a history of malignancy that has been treated with no recurrence within the last 2 years are not excluded
• •14. Females who are pregnant or breastfeeding
• •15. Use of Coenzyme Q10, either prescribed or purchased over-the-counter, are prohibited during the study, except for doses of up to 25mg/day which have been stable for 30 days prior to baseline. Higher doses require a 7 day washout prior to baseline.
• •16. Use of Vitamin E, either prescribed or purchased over-the-counter, are prohibited during the study, except for doses of up to 200IU/day which have been stable for 30 days prior to baseline. Higher doses require a 90 day washout prior to baseline.
• •17. Any changes to prescription medication in the 30 days prior to baseline
• •18. A history of a hypersensitivity reaction to any components of the study drug or structurally similar compounds including Coenzyme Q10 and idebenone
• •19. Unable to swallow tablets whole
• •20. Patients with histological or clinical evidence of established cirrhosis
• •21. Suffering from any other disease or condition which, in the opinion of the investigator, means that it would not be in the patient's best interest to participate in this study